Synergetic B-cell Immodulation in SLE
NCT02284984
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
16
Enrollment
OTHER
Sponsor class
Conditions
Lupus Erythematosus, Systemic
Interventions
DRUG:
Rituximab with belimumab
Sponsor
Leiden University Medical Center
Collaborators
[object Object]
[object Object]